Results 11 to 20 of about 768,553 (208)
HPV Vaccine Recommendations [PDF]
Pediatrics, 2012 This Policy Statement was retired June 2015. On October 25, 2011, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended that the quadrivalent human papillomavirus vaccine (Gardasil; Merck & Co, Inc, Whitehouse Station, NJ) be used routinely in males.
Michael T. Brady +12 more
openaire +2 more sources
Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China
Frontiers in Immunology, 2023 The incidence rate and mortality rate of cervical cancer have steadily increased in young women in China. Therefore, it is critical to improve HPV vaccination rates, particularly for the younger population.
Mingzhu Li +4 more
doaj +1 more source
Prevalence and characteristics of HPV vaccine hesitancy among parents of adolescents across the US.
Vaccine, 2020 BACKGROUND While many clinicians encounter parents or adolescents who refuse HPV vaccine, little is known about the prevalence of hesitancy for HPV vaccine nationally or its association with vaccination. METHODS In April 2019, we surveyed families with
P. Szilagyi +12 more
semanticscholar +1 more source
Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial.
Journal of the National Cancer Institute, 2020 BACKGROUND Investigate the durability of vaccine efficacy (VE) against HPV16/18 infections and antibody response among non-randomized women who received a single-dose of the bivalent HPV vaccine compared to women who received multiple doses and ...
A. Kreimer +20 more
semanticscholar +1 more source
Therapeutic HPV vaccines [PDF]
Best Practice & Research Clinical Obstetrics & Gynaecology, 2018 High-risk human papillomavirus (HPV) infection is known to be a necessary factor for cervical and anogenital malignancies. Cervical cancers account for over a quarter of a million deaths annually. Despite the availability of prophylactic vaccines, HPV infections remain extremely common worldwide.
Hancock, G, Hellner, K, Dorrell, L
openaire +3 more sources
Resilience of HPV vaccine uptake in Denmark: Decline and recovery.
Vaccine, 2020 BACKGROUND Immunization programs' resilience to shocks is central to their success, but little empirical evidence documents resilience in action. We sought to characterize the decline of HPV vaccination in Denmark after negative media coverage and ...
P. R. Hansen +2 more
semanticscholar +1 more source
Special Issue: HPV and HPV Vaccines [PDF]
Viruses, 2022 Our fundamental understanding of papillomaviruses and their interactions with their host, including their role in cancer and how the immune system responds to them, has made the elimination of cervical cancer a realistic global health goal [...]
openaire +3 more sources
Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.
Lancet Public Health, 2020 BACKGROUND Funding for human papillomavirus (HPV) vaccination in Japan began in 2010 for girls aged 12-16 years, with three-dose coverage initially reaching more than 70%. On June 14, 2013, 2 months after formal inclusion in Japan's national immunisation
K. Simms +4 more
semanticscholar +1 more source
BMC Public Health, 2016 Background Although female sex workers (FSWs) are a well-known high-risk group for Human Papillomavirus (HPV) infections, few tailored intervention programmes for HPV have been established worldwide. The lack of reliable data on the prevalence of HPV and
Alex Vorsters +8 more
doaj +1 more source
A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. [PDF]
PLoS Medicine, 2010 BACKGROUND: Information on factors that influence parental decisions for actual human papillomavirus (HPV) vaccine receipt in publicly funded, school-based HPV vaccine programs for girls is limited.
Gina Ogilvie +11 more
doaj +1 more source